MEDI speeds Ethyol reacquisition

MedImmune (MEDI) said it will reacquire U.S. rights to the chemoprotective Ethyol amifostine from Alza Corp., a subsidiary of Johnson & Johnson (JNJ), by October 1, six months sooner than originally a...